Expanding evidence suggested that targeting proinflammatory cytokines exhibited protective effects on NAFL/NASH in preclinical trials, including IL-27, IL-17, IL-11, IL-1, and TNFα, ensemble a significant portion of anti-inflammatory strategy to treat NAFL/NASH. Here, IL27 is linked to non-alcoholic fatty liver.